First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Completed · Phase 1 · NCT04000282
Conditions: Plasma Cell Myeloma
At a glance
- Research payments reported, 2025
- $50,427
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 37
About the trial
- Sponsor
- Sanofi
- Tested
- SAR442085 (drug)
- Dates
- Started 2019-08-19; completion 2023-09-04
- Results posted
- Not yet
Primary Objectives: * Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B * Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM Secondary Objectives: * To characterize the safety profile of SAR442085 * To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent * To evaluate the potential immunogenicity of SAR442085 * To assess preliminary evidence of antitumor activity in th…
From ClinicalTrials.gov, last updated 2025-09-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $50,427 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $50,427
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.